Transmembrane serine protease 4 expression in the prognosis of radical resection for biliary tract cancer

Table 2 Univariate and multivariate overall survival analyses of poor prognostic factors (n = 85)

Factors	Univariate			Multivariate
	Total patients, (n = 85), n(%)	MST (months)	P value	HR	95%CI	P value
Age, years
< 80	62 (73)	37.8	0.718
≥ 80	23 (27)	58.7
Sex
Male	45 (53)	37.2	0.378
Female	40 (47)	46.5
Neoadjuvant chemotherapy
Yes	3 (4)	36.0	0.956
No	82 (96)	46.5
Preoperative CA 19-9 level, U/mL
< 37	55 (65)	46.5	0.504
≥ 37	30 (35)	43.4
TMPRSS4
Positivity	46 (54)	25.3	< 0.001	2.33	1.08-5.08	0.032
Negativity	39 (46)			1.0
Histology, tub1/tub2
Yes	68 (80)	46.5	0.752
No	17 (20)	36.0
Tumor stage, pT3/T4
Yes	24 (28)	22.0	0.002	2.26	1.06-4.81	0.035
No	61 (72)	59.4		1.0
Pathological tumor size, mm
< 30	43 (51)		0.017	1.0
≥ 30	42 (49)	33.7		1.32	0.65-2.65	0.439
Lymphatic invasion (ly)
Yes	22 (26)	16.3	< 0.001	1.33	0.62-2.84	0.461
No	63 (74)	75.3		1.0
Venous invasion (v)
Yes	34 (40)	22.0	< 0.001	1.93	0.91-4.07	0.086
No	51 (60)	59.4		1.0
Neural invasion (ne)
Yes	39 (46)	33.3	0.058	0.60	0.26-1.40	0.237
No	46 (54)	58.7		1.0
Tumor infiltrative type c (IFN c)
Yes	13 (15)	33.7	0.081	1.18	0.58-2.42	0.648
No	72 (85)	58.7		1.0
Lymph node metastasis
Yes	40 (47)	25.6	0.004	1.44	0.60-3.46	0.412
No	45 (53)	75.3		1.0
Resection status,
R0	67 (79)	46.6	0.022	1.0
R1	18 (21)	24.5		2.21	1.08-4.52	0.030
Adjuvant chemotherapy
Yes	49 (58)	36.0	0.229
No	36 (42)	75.3

CA19-9: Carbohydrate antigen 19-9; CI: Confidence interval; HR: Hazard ratio; MST: Median survival time; tub1: Well-differentiated tubular adenocarcinoma; tub2: moderately differentiated tubular adenocarcinoma; TMPRSS4: Transmembrane serine protease 4.